Drugs / Auranofin
Auranofin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | RIDAURA | — | 1985-05-24 | fda.gov ↗ |
Trials 13 · a red edge is where a trial was stopped
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Auranofin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02770378 ↗ |
| Known as | Auranofina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366 ↗ |
| Known as | Auranofine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366 ↗ |
| Known as | NSC-321521 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366 ↗ |
| Known as | Ridaura | “Under an NIH priority to identify new drugs to treat class B parasitic agents, we performed high-throughput screens, which identified the activity of auranofin (Ridaura)...” PMID 27821451 ↗ Dec 2016 |
| Known as | SK&F 39162 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366 ↗ |
| Known as | SK-39162 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366 ↗ |
| Action | Inhibit | “This trial served as a proof-of-concept for whether inhibition of protein kinase C iota (PKCι) with auranofin and sirolimus provide antineoplastic effects in patients with...” PMID 41114938 ↗ Oct 2025 |
| Modality | Small molecule | “Auranofin is a gold-containing chemical salt available as 3mg capsules” NCT02736968 ↗ |
| Route | Oral | “Auranofin 6 mg orally in the morning / 6 mg orally in the evening” NCT01419691 ↗ |